ClinicalTrials.gov
ClinicalTrials.gov Menu

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01126736
Recruitment Status : Unknown
Verified December 2014 by Eisai Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 20, 2010
Last Update Posted : January 26, 2015
Sponsor:
Collaborator:
Quintiles, Inc.
Information provided by (Responsible Party):
Eisai Inc.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Actual Primary Completion Date : December 2012
  Estimated Study Completion Date : May 2015

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 August 25, 2017
September 22, 2017